Pierre Fabry forges I/O discovery pact; Actinium surges on CHMP support
→ France’s Pierre Fabre struck a deal with H-Immune SAS to develop new immunotherapies, utilizing H-Immune’s technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics. “This transaction strengthens Pierre Fabre’s position in the areas of immuno-oncology and novel cutting-edge biotherapeutics,” said Laurent Audoly, head of R&D of Pierre Fabre Pharmaceuticals.
→ Shares of Actinium Pharmaceuticals surged 11% this morning after the biotech reported that the CHMP in Europe provided positive scientific advice on the approval pathway for Iomab-B, signing off on its Phase III plans. Sandesh Seth, Executive Chairman of Actinium, said: “We are excited that the EMA finds the design, endpoints and statistical analysis of the Iomab-B SIERRA trial acceptable.”